| | Characteristic | Total | Relapse group | Nonrelapse group | value | | (N = 76) | (n = 46) | (n = 30) |
| | Male, n (%) | 53 (69.7) | 30 (65.2) | 23 (76.7) | >0.05 | | Age (years) | 38.0 (28.8, 48.2) | 42.0 (31.2, 48.8) | 33.0 (26.0, 46.8) | >0.05 | | BMI (kg/m2) | 24.4 ± 3.5 | 24.8 ± 3.4 | 23.8 ± 3.8 | >0.05 | | Disease duration (years) | 9.0 (4.8, 13.0) | 9.5 (5.0, 13.0) | 8.0 (4.2, 10.0) | >0.05 | | Age at disease onset (years) | 28 (21.0, 39.2) | 30 (24.2, 42.8) | 23.5 (18.0, 36.0) | >0.05 | | Comorbidities, n (%) | | Psoriatic arthritis | 6 (7.9) | 5 (10.9) | 1 (3.3) | >0.05 | | Obesity | 11 (14.5) | 8 (17.4) | 3 (10) | >0.05 | | Hypertension | 8 (10.5) | 5 (10.9) | 3 (10.0) | >0.05 | | Dyslipidemia | 19 (25.0) | 13 (28.3) | 6 (20.0) | >0.05 | | Diabetes | 6 (7.9) | 5 (10.9) | 1 (3.3) | >0.05 | | Hepatitis B | 7 (9.2) | 6 (13.0) | 1 (3.3) | >0.05 | | Latent tuberculosis | 9 (11.8) | 3 (6.5) | 6 (20.0) | >0.05 | | Depression | 3 (3.9) | 1 (2.2) | 2 (6.7) | >0.05 | | Comorbidities, n (%) | | | | 0.006 | | Yes | 45 (59.2) | 33 (71.7) | 12 (40.0) | | | No | 31 (40.8) | 13 (28.3) | 18 (60.0) | | | Prior biologic therapy, n (%) | 9 (11.8) | 8 (17.4) | 1 (3.3) | >0.05 | | Duration of guselkumab treatment, n (%) | | | | >0.05 | | 4 weeks (2 doses of injections) | 39 (51.3) | 22 (47.8) | 17 (56.7) | | | 12 weeks (3 doses of injections) | 5 (6.6) | 4 (8.7) | 1 (3.3) | | | 20 weeks (4 doses of injections) | 31 (40.8) | 19 (41.3) | 12 (40.0) | | | 28 weeks (5 doses of injections) | 0 | 0 | 0 | | | 36 weeks (6 doses of injections) | 1 (1.3) | 1 (2.2) | 0 | | | PASI score at baseline | 11.7 (7.5, 20.5) | 11.9 (7.9, 18.5) | 11.6 (7.2, 21.0) | >0.05 | | PGA score at baseline | 3 (3, 4) | 3 (3, 4) | 3 (3, 4) | >0.05 | | DLQI score at baseline | 12.0 ± 4.8 | 11.7 ± 4.8 | 12.4 ± 5.0 | >0.05 | | PASI score at relapse | NA | 4.6 (1.6, 8.4) | NA | — | | Duration of relapse (days) | 203.5 (167, 338) | 201 (159, 314) | 235 (173, 377) | >0.05 |
|
|
